The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
Open accessAbstract
Atherosclerosis develops rapidly in patients with diabetes or renal insufficiency. Plasma lipoprotein profiles are frequently abnormal in these conditions and reflect an elevation in the level of the apoprotein B (ApoB)-containing components very low density lipoprotein (VLDL) and low density lipoprotein (LDL). High levels of circulating advanced glycation end products (AGEs) also occur in diabetes and end-stage renal disease (ESRD). These products arise from glucose-derived Amadori products and include AGE-modified peptides (AGE-peptides) which result from the catabolism of AGE-modified tissue proteins. AGE-peptides have been shown to crosslink protein amino groups and to accumulate in plasma as a consequence of renal insufficiency. To address potential mechanisms for the dyslipidemia of diabetes and ESRD, we investigated the possibility that circulating AGEs react directly with plasma lipoproteins to prevent their recognition by tissue LDL receptors. AGE-specific ELISA showed a significantly increased level of AGE-modified LDL in the plasma of diabetic or ESRD patients compared with normal controls. AGE-LDL formed readily in vitro when native LDL was incubated with either synthetic AGE-peptides or AGE-peptides isolated directly from patient plasma. LDL which had been modified by AGE-peptides in vitro to the same level of modification as that present in the plasma of diabetics with renal insufficiency exhibited markedly impaired clearance kinetics when injected into transgenic mice expressing the human LDL receptor. These data indicate that AGE modification significantly impairs LDL-receptor-mediated clearance mechanisms and may contribute to elevated LDL levels in patients with diabetes or renal insufficiency. This hypothesis was further supported by the observation that the administration of the advanced glycation inhibitor aminoguanidine to diabetic patients decreased circulating LDL levels by 28%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,760
Epstein, F. H., Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., & Witztum, J. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201407 · Cited by 6,427
The Pathogenesis of Atherosclerosis — An Update
Ross, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140806 · Cited by 4,877
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
Flier, J. S., Underhill, L. H., Brownlee, M., Cerami, A., & Vlassara, H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805193182007 · Cited by 2,511
Self-citationThe Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 1,906
Bucala, R., Tracey, K. J., & Cerami, A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115014 · Cited by 1,165
Self-citationAminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking
Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., & Cerami, A. (1986) · Science · doi:10.1126/science.3487117 · Cited by 1,146
Self-citationAdvanced Glycosylation End Products in Patients with Diabetic Nephropathy
Makita, Z., Radoff, S., Rayfield, E. J., Yang, Z., Skolnik, E., Delaney, V., Friedman, E. A., Cerami, A., & Vlassara, H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109193251202 · Cited by 918
Self-citationAccelerated age-related browning of human collagen in diabetes mellitus.
Monnier, V. M., Kohn, R. R., & Cerami, A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.2.583 · Cited by 671
Self-citationCachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue Remodeling
Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A., & Pasagian, A. (1988) · Science · doi:10.1126/science.3259727 · Cited by 597
Self-citationLipid advanced glycosylation: pathway for lipid oxidation in vivo.
Bucala, R., Makita, Z., Koschinsky, T., Cerami, A., & Vlassara, H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6434 · Cited by 571
Self-citationAdvanced Glycosylation: Chemistry, Biology, and Implications for Diabetes and Aging
Bucala, R., & Cerami, A. (1992) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60961-8 · Cited by 526
Self-citationImmunochemical detection of advanced glycosylation end products in vivo.
Makita, Z., Vlassara, H., Cerami, A., & Bucala, R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42741-x · Cited by 491
Self-citationMahley, R. W., Innerarity, T. L., Pitas, R. E., Weisgraber, K. H., Brown, J. H., & Gross, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)66966-8 · Cited by 383
Esposito, C., Gerlach, H., Brett, J., Stern, D., & Vlassara, H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.4.1387 · Cited by 380
Self-citationReactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
Makita, Z., Bucala, R., Rayfield, E. J., Fuh, H., Manogue, K. R., Cerami, A., Viassara, H., Friedman, E. A., Kaufman, A. M., Korbet, S. M., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92935-1 · Cited by 373
Self-citationNonenzymatic Glucosylation of Low-Density Lipoprotein Alters Its Biologic Activity
Witztum, J. L., Mahoney, E. M., Branks, M. J., Fisher, M., Elam, R., & Steinberg, D. (1982) · Diabetes · doi:10.2337/diab.31.4.283 · Cited by 352
Mahley, R. W., Innerarity, T. L., Weisgraber, K. H., & Oh, S. Y. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109518 · Cited by 316
Schnider, S. L., & Kohn, R. R. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110198 · Cited by 312
Vlassara, H., Brownlee, M., & Cerami, A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.17.5588 · Cited by 309
Self-citationDiabetes as an atherogenic factor
Ruderman, N. B., & Haudenschild, C. (1984) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(84)90011-2 · Cited by 282
Kikugawa, K., Kojima, T., Yamaki, S., & Kosugi, H. (1992) · Analytical Biochemistry · doi:10.1016/0003-2697(92)90102-d · Cited by 264
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita, Z., Vlassara, H., Rayfield, E., Cartwright, K., Friedman, E., Rodby, R., Cerami, A., & Bucala, R. (1992) · Science · doi:10.1126/science.1411574 · Cited by 251
Self-citationJensen, T., Stender, S., & Deckert, T. (1988) · Diabetologia · doi:10.1007/bf00276846 · Cited by 231
Hogan, M., Cerami, A., & Bucala, R. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115928 · Cited by 209
Self-citationKesaniemi, Y. A., Witztum, J. L., & Steinbrecher, U. P. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110849 · Cited by 202
Lipoprotein-receptor interactions
Innerarity, T. L., Pitas, R. E., & Mahley, R. W. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)29091-6 · Cited by 186
Collagen Aging In Vitro by Nonenzymatic Glycosylation and Browning
Kohn, R. R., Cerami, A., & Monnier, V. M. (1984) · Diabetes · doi:10.2337/diab.33.1.57 · Cited by 183
Self-citationThe chemistry of the Maillard reaction under physiological conditions: a review.
Njoroge, F. G., & Monnier, V. M. (1989) · PubMed · Cited by 163
Hofmann, S. L., Russell, D. W., Brown, M. S., Goldstein, J. L., & Hammer, R. E. (1988) · Science · doi:10.1126/science.3344433 · Cited by 117
Lipoprotein disorders in diabetes mellitus
Brown, W. V. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30180-8 · Cited by 113
Hiramatsu, K., Bierman, E. L., & Chait, A. (1985) · Diabetes · doi:10.2337/diab.34.1.8 · Cited by 100
Glycosylated haemoglobin: measurement and clinical use.
Peacock, I. (1984) · Journal of Clinical Pathology · doi:10.1136/jcp.37.8.841 · Cited by 69
Cited by
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Advanced glycation endproducts—role in pathology of diabetic complications
Ahmed, N. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.09.004 · Cited by 1,455
BASTA, G. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.05.001 · Cited by 999
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Koschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., & Vlassara, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6474 · Cited by 792
Self-citation
Metadata
- Authors
- Bucala, R., Makita, Z., Vega, G., Grundy, S., Koschinsky, T., Cerami, A., & Vlassara, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-09-27
- Volume
- 91
- Issue
- 20
- Pages
- 9441-9445
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2056258976
- Cited by
- 474
- References
- 34
- FWCI
- 14.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.